|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 非酒精性脂肪性肝病诊疗指南显示文摘非酒精性脂肪性肝病(NAFLD)是指除外酒精和其他明确的损肝因素所致的,以弥漫性肝细胞大泡性脂肪变为主要特征的临床病理综合征,包括单纯性脂肪肝以及由其演变的脂肪性肝炎(NASH)和肝硬化,胰岛素抵抗和遗传易感性与其发病关系密切。随着肥胖和糖尿病的发病率增加,NAFLD现已成为我国常见的慢性肝病之一,严重危害人民健康。为进一步规范NAFLD的诊断、治疗和疗效评估,中华医学会肝病学分会脂肪肝和酒精性肝病学组组织国内有关专家,在参考国内外最新研究成果的基础上,按照循证医学的原则,制定了《非酒精性脂肪性肝病诊疗指南》(以下简称(《指南》)。其中推荐的意见所依据的证据共分为3个级别5个等次,文中以括号内斜体罗马数字表示,推荐意见的证据分级,参见Ⅸ酒精性肝病诊疗指南》表1。 | Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association. | 2006 | 中华肝脏病杂志2006，14，3： | 1509 |
| 2 | 酒精性肝病诊疗指南显示文摘酒精性肝病是由于长期大量饮酒所致的肝脏疾病。初期通常表现为脂肪肝,进而可发展成酒精性肝炎、酒精性肝纤维化和酒精性肝硬化,严重酗酒时可诱发广泛肝细胞坏死甚或肝功能衰竭,该病是我国常见的肝脏疾病之一,严重危害人民健康。为进一步规范酒精性肝病的诊断和治疗,中华医学会肝病学分会脂肪肝和酒精性肝病学组组织国内有关专家,在参考国内外最新研究成果的基础上,按照循证医学的原则,制订了本《指南》。其中推荐的意见所依据的证据等级共分为3个级别5个等次,见表1,文中以括号内斜体罗马数字表示。 | Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association. | 2006 | 中华肝脏病杂志2006，14，3： | 271 |
| 3 | 非酒精性脂肪性肝病诊疗指南显示文摘 | Fattly Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association. | 2007 | 实用肝脏病杂志2007，10，1： | 145 |
| 4 | 尿激酶治疗急性心肌梗塞多中心临床试验1406例总结显示文摘为观察尿激酶天普洛欣(UKTP)经静脉溶栓治疗急性心肌梗塞(AMI)的临床有效性及安全性。收集协作组148家医院1994年11月至1996年4月经静脉UKTP溶栓治疗AMI患者1406例,观察临床疗效、副作用及病死率等。其中124例行90分钟冠状动脉造影评价梗塞血管开通情况。结果:梗塞血管临床再灌注率为73.5%,90分钟冠状动脉造影血管开通率为72.6%,5周总病死率为7.8%(109/1406),轻度出血10.2%(143/1406),中重度出血0.43%(6/1406),脑出血0.50%(7/1406)。老年(>65岁)甚至高龄(>75岁)患者溶栓及距发病超过6小时者,其用药仍然安全有效,UKTP合适的用药剂量可能为150万U左右。结果提示UKTP治疗AMI安全有效。 | The collaborative study group for national multicenter clinical trial of urokinase thrombolytic therapy (Correspondence: Hu Dayi, Xu Zhimin. Beijing Red Cross Chao Yao Hospital, Beijing 100020) | 1997 | 中华心血管病杂志1997，25，3： | 139 |
| 5 | 不稳定性心绞痛、急性非Q波心肌梗死不同抗栓疗法的对比研究显示文摘目的 观察不同抗栓方案对急性冠状动脉综合征心脏事件、出血风险和预后的影响。方法 本研究为前瞻性、多中心、随机、开放试验 ,入选患者随机分为静脉滴注普通肝素组和皮下注射低分子量肝素组。入选对象为不稳定性心绞痛或非Q波心肌梗死 ,入选前 4 8小时以内至少有一次心绞痛发作 ,ST段无抬高。肝素 10 0IU/kg静注 ,续 10 0 0IU/h ,维持活化的部分凝血活酶时间 (APTT)或活化的全血凝固时间 (ACT)于正常的 1 5~ 2 0倍 ,连续 7日。低分子量肝素 0 4~ 0 6ml,每日两次皮下注射 ,连续 7日。主要观察终点 :随访治疗 3 0日内发生急性心肌梗死、心脏性或非心脏性死亡和药物治疗无法控制心绞痛 ,需行急性血运重建术。住院至少 7日 ,随访至治疗后 3 0日。结果 本研究共入选符合条件的患者 4 0 2例 ,两组在性别、年龄、心血管危险因素和心绞痛发作方面差异无显著性。治疗后 7日 ,两组用药期间平均胸痛发作次数差异无显著性 ,但肝素组有更多的患者需口服硝酸甘油缓解胸痛 ;病死率在低分子量肝素组较普通肝素组低 ,两组比较P值为 0 0 62 ,复合终点事件 (死亡、心肌梗死和紧急血管重建 )在低分子量肝素组明显下降。低分子量肝素组出血事件明显少于肝素组。治疗开始后 3 0日 ,低分子量肝素组死亡和复合终点事? | Clinical Collaborative Study Group of Low Molecular Weight Heparin (Correspondent: HU Dayi, XU Juntang. Beijing Red Cross Chaoyang Hospital, Beijing University of Medical Sciences, Beijing 100020, China) | 2000 | 中华心血管病杂志2000，28，1： | 172 |
| 6 | 酒精性肝病诊疗指南显示文摘 | Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association. | 2007 | 实用肝脏病杂志2007，10，1： | 73 |
| 7 | Report on Childhood Obesity in China (1) Body Mass Index Reference for Screening Overweight and Obesity in Chinese School-age Children显示文摘Purpose To establish and propose a national body mass index (BMI) reference for screening overweight and obesity in Chinese school-age children and adolescents. Methods 2000 CNSSCH (Chinese National Survey on Students Constitution and Health) data, including 216 620 primary and secondary school students aged 7 to 18 years old, were used as a reference population. Compared with those of the NCHS internatioanl reference, three temporary sets of cut-off BMI were proposed by testing different combinations of P8s, P9o, and P95. When physiological and biochemical measures between and among 'obesity','overweight', and 'normal weight' groups were taken into consideration, set Ⅱ was selected to be the most appropriate one.The sex-age-specific curves were then plotted and smoothed by using B-spline method. Results Based on the samples from costal developed metropolis, the BMI curves successfully overcame the shortcomings of lower and level-off tendency of the Chinese total population. Temporary set Ⅱ, composed by cut-offs of P85 for overweight and P95 for obesity, was finally selected by its sensitivity and peculiarity. BMI 24 and 28 were used as cut-offs for overweight and obesity for both males and females aged 18 years old. These cut-offs, consistent with Chinese Adult's Reference, was proposed as the Body mass index reference for screening overweight and obesity in Chinese school-age children and adolescents. Conclusion The new reference clearly showed its superiorty in both prospectivity and actuality. The proposed reference minimized the gaps of the BMI curve between Chinese adolescents and the international reference. Most importantly was that it was consistent with the Eastern Asia ethnic characteristics of body fatness growth. It was therefore proposed by the Working Group on Obesity in China (WGOC) to use it as an nationwide reference for screening overweight and obesity of school-age children and adolescents in China. | COOPERATIVE STUDY ON CHILDHOOD OBESITY WORKING GROUP ON OBESITY IN CHINA (WGOC) | 2005 | Biomedical and Environmental Sciences2005，18，6： | 57 |
| 8 | 女性急性心肌梗塞的临床特点显示文摘目的为了解女性急性心肌梗塞(AMI)的临床特点,以提高防治效果。方法对北京地区防治冠心病协作组1990~1991年连续收治的1614例患者(男1185,女429),进行男女比较分析。根据患者年龄分为(<45,45~54,55~64,≥65岁)四组,比较患者例数、并发症及病死率。结果四组男与女患者比例分别为17.8:1,6.1:1,3.2:1和1.8:1。女性并发心源性休克者明显多于男性。发病4周病死率,女性14.7%明显高于男性9.4%。在45~54岁组内,差异亦有显著性(1.2%比0.7%)。结论提示与年龄有关的雌激素水平变化对女性AMI临床特点有明显的影响。 | Beijing Collaborative Study Group of Coronary Heart Disease 100700 (correspondewce: Beijing General Hospital, PLA, Beijing 100700) | 1998 | 中华心血管病杂志1998，26，3： | 47 |
| 9 | 五个月短程化疗及六个月全程间歇方案治疗菌阳肺结核的临床对照研究显示文摘目的考核利福喷丁(L)的疗效;缩短疗程或全程间歇以减少用药次数;观察全程应用吡嗪酰胺(Z)对疗效及毒副反应的影响。方法以利福平(R)为对照,采用5个月疗程方案(Ⅰ组2SHRZ/3R2H2Z2,Ⅱ组2SHRZ/3L1H2Z2)、6个月全间歇方案(Ⅲ组2S3H3R3Z3/4L1H2Z2,Ⅳ组2S3H3R3Z3/4L1H2E2),观察Z的全程应用结果,巩固期以乙胺丁醇(E)为对照。366例初治菌阳肺结核随机分入以上4组。结果(1)339例完成疗程者中329例治疗成功,满疗程时痰菌阴转率Ⅰ~Ⅳ组分别为970%、941%、1000%、972%。X线病灶有效率依序为960%、976%、1000%和944%。5个月组与6个月组空洞关闭率分别为77%及76%。各组相互比较均无显著性差异(P>0.05),未见严重副作用。(2)305例完成3年随访,Ⅰ、Ⅱ、Ⅲ、Ⅳ组细菌学加X线复发分别为2、3、6和3例。结论本研究结果进一步证明L是长效、高效、安全、便于督导的新药;巩固期用Z无必要;现有基本药物合理联用有可能缩短疗程为5个月,值得进一步研究。 | National Cooperative Group On Clinical Study of Pulmonary Tuberculosis (Report prepared by Chu Naihui , Yan Biya, Zhu Lizhen). Beijing Tuberculosis and Thoracic Tumor Institute, Beijing 101149 | 1998 | 中华结核和呼吸杂志1998，21，7： | 26 |
| 10 | Clinical significance of diabetes on symptom and patient delay among patients with acute myocardial infarction——an analysis from China Acute Myocardial Infarction(CAMI) registry显示文摘Background Diabetes is frequently associated with poor prognosis among acute myocardial infarction(AMI)patients.Patients with these comorbidities often have atypical symptoms and subsequent delay in treatment.Few studies have reported detailed AMI symptoms in patients with diabetes.This study compared AMI symptoms and presentation characteristics between diabetics and non-diabetics.Methods We included patients from the China AMI registry diagnosed with AMI between January 2013 and September 2014.Baseline characteristics,symptomology,and delay in treatment were compared between diabetics and non-diabetics.Multivariable logistic regression analysis was used to explore independent predictors of atypical symptoms.Results A total of 4450(20.2%)patients had diabetes.They were older,more often women,higher in body mass index,and more likely to have non-ST segment elevation myocardial infarction.Fewer diabetic patients presented with persistent precordial chest pain(63.1%vs.68%,P<0.0001),diaphoresis(60.1%vs.65.6%,P<0.0001),fatigue(16.7%vs.18.3%,P=0.0123),and incontinence(0.4%vs.0.7%,P=0.0093).Time to hospital presentation was longer among patients with diabetes than those without.In multivariable analysis,diabetes was identified as an independent predictor of atypical symptoms(OR:1.112,95%CI:1.034?1.196).Conclusions Our study is the first large-scale study providing evidence that diabetics are less likely to present with typical chest pain and more likely to experience treatment delay when suffering from an AMI.Our results may increase clinician awareness of recognizing AMI patients rapidly to reduce diagnosis and treatment delay,particularly in the context of diabetes. | Rui FU Si-Dong LI Chen-Xi SONG Jing-Ang YANG Hai-Yan XU Xiao-Jin GAO Yi XU Jian-Ping ZENG Jun-Nong LI Ke-Fei DOU Yue-Jin YANG on behalf of the CAMI Registry study group Beijing,China | 2019 | Journal of Geriatric Cardiology2019，16，5： | 21 |
| 11 | 马王堆帛书《式法》释文摘要显示文摘1973年湖南长沙马王堆三号汉墓出土的帛书,有一种在过去报道中通称“篆书阴阳五行”,其内容实际是选择吉凶时曰的数术,与湖北云梦睡虎地十一号秦墓所出竹简《曰书》相类,而更多与“式”的运作有关,今暂题为《式法》。目前《式法》的整理工作尚未全部完成,现选刊其中七部分的释文,供学术界研究。 | The Study Group for the Silk Books from Mawangdui | 2000 | 文物2000，，7： | 20 |
| 12 | 中国内地2型糖尿病合并高血压患者微量白蛋白尿检出率调查显示文摘目的调查内分泌科及心内科门诊中糖尿病合并高血压患者微量白蛋白尿(MA)检出率。方法多中心连续收集2型糖尿病合并高血压患者共2473例,采用统一调查表记录患者糖尿病、高血压控制情况及相关并发症,测量血压。采用 Micral-Ⅱ试纸半定量比色法筛查尿微量白蛋白。结果 2型糖尿病合并高血压患者 MA 的检出率为42.9%,大量白蛋白尿检出率17.0%。多因素回归分析显示,患者年龄、收缩压水平、空腹血糖水平以及 BMI 与糖尿病合并高血压患者 MA 的发生独立相关;除上述因素外,尚有糖尿病病程、应用利尿剂与大量白蛋白尿的发生独立相关。结论在2型糖尿病合并高血压患者中 MA 检出率极高,MA 筛查及强力降压治疗甚为重要。 | China's Mainland Microalbuminuria Prevalence Study Group Corresponding author:DU Jin,PAN Chang-yu.Department of Endocrinology,Chinese PLA General Hospital, | 2007 | 中华内科杂志2007，46，3： | 18 |
| 13 | 甲异靛治疗慢性粒细胞白血病 Ⅲ 期临床观察显示文摘目的:进一步考察甲异靛的疗效及副作用。方法:1994年3月~1995年7月中华医学会组织全国甲异靛治疗慢性粒细胞白血病(CML)Ⅲ期临床试验协作组,包括36个省级以上医疗单位,有402例CML患者进入临床观察,可评价疗效的有374例。结果:单一用药,每日75~150mg,总有效率为90.1%,缓解率为81.3%。初治患者疗效优于复治患者,缩脾效果好。获最佳疗效的时间平均为73.3天。副作用主要为不同程度的骨、关节、肌肉的疼痛,消化道反应轻微,近期与长期观察无心、肝、肾功能的损害,所有患者均未发生骨髓抑制。结论:甲异靛是一种新型的治疗CML的药物。 | Cooperative Study Group of Phase Ⅲ Clinical Trial on Meisoindico,Tianjin 300020 | 1997 | 中华血液学杂志1997，18，2： | 16 |
| 14 | 微粒化非诺贝特治疗高脂血症疗效和耐受性显示文摘上海市多中心、开放性、自身比较,观察微粒化非诺贝特200mg,每晚一次,治疗131例高脂血症病人4~8周的疗效和耐受性。男性76例,女性55例,平均年龄56.2±9.73岁,所属高血脂类型:Ⅱa型26例,Ⅱb型53例,Ⅳ型52例。治疗8周之后,Ⅱa和Ⅱb型患者血清总胆固醇明显降低(平均降低20%,P<0.01),Ⅱb和Ⅳ型患者血清甘油三酯明显降低(平均降低60%~63%,P<0.01),未出现严重不良反应,结论:微粒化非诺贝特特别适用于治疗Ⅱb和Ⅳ型高脂血症患者。4例合并有高尿酸血症者,治疗8周后,血尿酸平均降低59%。 | Zhu Junren, Han Qingqin. Zhongshan Hospital, Shanghai Medical University, Shanghai 100032 Shanghai multicenter clinical study group ) | 1997 | 中华心血管病杂志1997，25，3： | 16 |
| 15 | Toll-like receptor 4 and NOD2/CARD15 mutations in Hungarian patients with Crohn's disease: Phenotype-genotype correlations显示文摘AIM: To determine common NOD2/CARD15 mutations and TLR4 D299G polymorphism in Hungarian patients with CD.METHODS: A total of 527 unrelated patients with CD (male/female: 265/262, age: 37.1 (SD 7.6) years) and 200 healthy subjects were included. DNA was screened for possible NOD2/CARD15 mutations by denaturing highperformance liquid chromatography (confirmed by direct sequencing). TLR4 D299G was tested by PCR-RFLP.RESULTS: NOD2/CARD15 mutations were found in 185patients (35.1%) and in 33 controls (16.5%, P<0.0001).SNP8/R702W (10.8% vs 6%, P = 0.02), SNP13/3020insC (19.4% vs 5%, P<0.0001) and exon4 R703C (2.1% vs 0%, P = 0.02) mutations were more frequent in CD, while the frequency of SNP12/G908R was not increased. The frequency of TLR4 D299G was not different (CD: 9.9% vscontrols: 12.0%). Variant NOD2/CARD15 allele was associated with an increased risk for CD (ORhet = 1.71,95%CI = 1.12-2.6, P= 0.0001, ORtwo-riskalleles = 25.2,95%CI = 4.37- , P<0.0001), early disease onset (carrier:26.4 years vs non-carrier: 29.8 years, P = 0.0006), ileal disease (81.9% vs 69.5%, OR = 1.99, 95%CI = 1.29-3.08,P = 0.02, presence of NOD2/CARD15 and TLR4: 86.7% vs64.8%), stricturing behavior (OR = 1.69, 95%CI = 1.13-2.55,P = 0.026) and increased need for resection (OR=1.71,95%CI: 1.13-2.62, P= 0.01), but not with duration, extraintestinal manifestations, familial disease or smoking. TLR4exhibited a modifier effect: age of onset in wt/TLR4 D299G carriers: 27.4 years vs NOD2mut/TLR D299G: 23 years (P= 0.06), in NOD2mut/wt: 26.7 years.CONCLUSION: These results confirm that variant NOD2/CARD15 (R702W, R703C and 3020insC) alleles are associated with earlier disease onset, ileal disease,stricturing disease behavior in Hungarian CD patients. In contrast, although the frequency of TLR4 D299G polymorphism was not different from controls, NOD2/TLR4mutation carriers tended to present at earlier age. | Peter Laszlo Lakatos Laszlo Lakatos Ferenc Szalay Claudia Willheim-Polli Christoph (O|¨)sterreicher Zsolt Tulassay Tamas Molnar Walter Reinisch Janos Papp Gyula Mozsik Hungarian IBD Study Group Peter Ferenci | 2005 | World Journal of Gastroenterology2005，11，10： | 14 |
| 16 | Body-mass index correlates with severity and mortality in acute pancreatitis: A meta-analysis显示文摘BACKGROUND Obesity rates have increased sharply in recent decades. As there is a growing number of cases in which acute pancreatitis(AP) is accompanied by obesity, we found it clinically relevant to investigate how body-mass index(BMI) affects the outcome of the disease.AIM To quantify the association between subgroups of BMI and the severity and mortality of AP.METHODS A meta-analysis was performed using the Preferred Reporting Items for Systematic Review and Meta-Analysis(PRISMA) Protocols. Three databases(PubMed, EMBASE and the Cochrane Library) were searched for articles containing data on BMI, disease severity and mortality rate for AP. Englishlanguage studies from inception to 19 June 2017 were checked against our predetermined eligibility criteria. The included articles reported all AP cases with no restriction on the etiology of the disease. Only studies that classified AP cases according to the Atlanta Criteria were involved in the severity analyses. Odds ratios(OR) and mean differences(MD) were pooled using the random effects model with the DerSimonian-Laird estimation and displayed on forest plots. The meta-analysis was registered in PROSPERO under number CRD42017077890.RESULTS A total of 19 articles were included in our meta-analysis containing data on 9997 patients. As regards severity, a subgroup analysis showed a direct association between AP severity and BMI. BMI < 18.5 had no significant effect on severity;however, BMI > 25 had an almost three-fold increased risk for severe AP in comparison to normal BMI(OR = 2.87, 95%CI: 1.90-4.35, P < 0.001). Importantly,the mean BMI of patients with severe AP is higher than that of the non-severe group(MD = 1.79, 95%CI: 0.89-2.70, P < 0.001). As regards mortality, death rates among AP patients are the highest in the underweight and obese subgroups. A BMI < 18.5 carries an almost two-fold increase in risk of mortality compared to normal BMI(OR = 1.82, 95%CI: 1.32-2.50, P < 0.001). However, the chance of mortality is almost equal in the normal BMI and BMI 25-30 subgroups. A BMI >30 results in a three times higher risk of mortality in comparison to a BMI < 30(OR = 2.89, 95%CI: 1.10-7.36, P = 0.026).CONCLUSION Our findings confirm that a BMI above 25 increases the risk of severe AP, while a BMI > 30 raises the risk of mortality. A BMI < 18.5 carries an almost two times higher risk of mortality in AP. | Dalma Dobszai Péter Mátrai Zoltan Gyongyi Dezso Csupor Judit Bajor Balint Eross Alexandra Mikó Lajos Szakó Agnes Meczker Roland Hágendorn Katalin Márta Andrea Szentesi Péter Hegyi on behalf of the Hungarian Pancreatic Study Group | 2019 | World Journal of Gastroenterology2019，25，6： | 11 |
| 17 | Angiographic characteristics and in-hospital mortality among patients with ST-segment elevation myocardial infarction presenting without typical chest pain: an analysis of China Acute Myocardial Infarction registry显示文摘Background:Patients with ST-segment elevation myocardial infarction(STEMI)who present without typical chest pain are associated with a poor outcome.However,whether angiographic characteristics are related to a higher risk of mortality in this population is unclear.This study aimed to investigate whether the higher mortality risk in patients with STEMI without chest pain could be explained by their'high-risk'angiographic characteristics.Methods:We used data of 12,145 patients with STEMI who was registered in China Acute Myocardial Infarction registry from January 2013 to September 2014.We compared the infarct-related artery(IRA),thrombolysis in myocardial infarction(TIMI)flow grade in the IRA,and other angiographic characteristics between patients without and those with chest pain.Multivariable logistic regression model was used to identify independent risk factor of in-hospital mortality.Results:The 2922(24.1%)patients with STEMI presented without typical chest pain.These patients had a higher TIMI flow grade(mean TIMI flow grade:1.00 vs.0.94,P=0.02)and a lower rate of IRA disease of the left anterior descending artery(44.6%vs.51.2%,χ^2=35.63,P<0.01)than did those with typical chest pain.Patients without chest pain were older,more likely to have diabetes,longer time to hospital and higher Killip classification,and less likely to receive optimal medication treatment and primary percutaneous coronary intervention and higher In-hospital mortality(3.3%vs.2.2%,χ^2=10.57,P<0.01).After adjusting for multi-variables,presentation without chest pain was still an independent predictor of in-hospital death among patients with STEMI(adjusted odds ratio:1.36,95%confidence interval:1.02–1.83).Conclusions:Presentation without chest pain is common and associated with a higher in-hospital mortality risk in patients with acute myocardial infarction.Our results indicate that their poor prognosis is associated with baseline patient characteristics and delayed treatment,but not angiographic lesion characteristics.Clinical trial registration:NCT01874691,http://gffzzd3f38a9638994581sbpqx0ckubq906x6f.ffgz.tsg.suse.edu.cn. | Chen-Xi Song Rui Fu Jin-Gang Yang Hai-Yan Xu Xiao-Jin Gao Chun-Yue Wang Yang Zheng Shao-Bin Jia Ke-Fei Dou Yue-Jin Yang on behalf of the CAMI Registry study group | 2019 | Chinese Medical Journal2019，，19： | 11 |
| 18 | 海洋工程技术强国战略显示文摘为了推进海洋强国建设,中国工程院于2011年启动了'中国海洋工程与科技发展战略研究'重大咨询项目研究。本文从海洋探测、海洋运载、海洋能源、海洋生物资源、海洋环境和海陆关联6个重要工程技术领域开展咨询调查研究,系统分析了海洋工程与科技发展的机遇与战略需求,提出了发展战略和任务。明确提出建设海洋强国,科技必须先行,必须首先建设海洋工程技术强国,建议国家加大海洋工程技术的发展力度,加快实施海洋工程科技创新驱动和现代海洋产业发展推进两大计划。 | Task Force for the Study on Development Strategy of China’s Marine Engineering and Technology Comprehensive Research Group | 2016 | 中国工程科学2016，18，2： | 9 |
| 19 | 阿柏西普玻璃体腔注射和光动力疗法治疗中国新生血管性老年性黄斑变性患者的疗效对比:SIGHT研究显示文摘目的对比观察玻璃体注射阿柏西普(IAI)和光动力疗法(PDT)治疗中国继发于新生血管性老年性黄斑变性(nAMD)的经典为主型脉络膜新生血管(CNV)患者的安全性和有效性。方法随机、双盲、多中心为期52周(2011年12月至2014年8月)的Ⅲ期临床研究。研究注册码NCT01482910。入组患者按照3:1比例随机分为IAI组、PDT→IAI组。IAI组患者在基线和第4、8、16、24、32、40、48周时接受2 mg IAI治疗,第28、36周时分别接受假注射治疗。PDT→IAI组患者在基线时均强制接受1次PDT治疗,第12、24周时若满足PDT再治疗条件,则再次予以PDT治疗;基线和第4、8、16、24周时接受假注射治疗,第28、32、36、40、48周时接受2 mg IAI治疗。报告的主要有效性结果为第28周时平均BCVA相较基线的变化和第52周时的结果。安全性评价包括发生治疗相关不良事件(TEAEs)患者百分比。结果入组304例患者中,IAI组、PDT→IAI组分别为228、76例。第28周时,IAI组、PDT→IAI组患者平均BCVA较基线变化值分别为+14.0、+3.9个字母;第52周时,两组患者BCVA较基线变化值分别为+15.2、+8.9个字母,差异为+6.2个字母(95% CI 2.6~9.9,P=0.000 9)。第52周时,两组患者平均中心凹视网膜厚度分别下降?189.6、?170.0 μm。IAI组中BCVA提高最为显著者为年龄<65岁、活动性CNV面积<总病灶面积50%者。IAI组、PDT→IAI组患者眼部最常见TEAEs为黄斑纤维化[11.8%(27/228)、6.6%(5/76)]、BCVA下降[6.6%(15/228)、21.1%(16/76)]。抗血小板研究合作组定义的动脉血栓栓塞事件3例,但均被认为与药物无关。结论中国nAMD患者阿柏西普治疗效果优于PDT。阿柏西普疗效在全部患者中均可持续至第52周。不良事件的发生率与已知的阿柏西普安全性数据一致。 | 黎晓新 陈有信 张军军 许迅 张风 ChuiMing Gernmy Cheung RuiYu HusainKazmi OlafSowade OliverZeitz on behalf of the SIGHT study group | 2019 | 中华眼底病杂志2019，35，2： | 9 |
| 20 | Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2:A project of the Kyushu University Liver Disease Study Group显示文摘瞄准:决定一座干扰素高山的功效哈并且为感染遗传型 2 的丙肝病毒(HCV ) 的日本病人的 ribavirin 联合治疗,多中心研究回顾地被分析。方法:总共,有 HCV 遗传型 2 的 173 个病人每天一个星期和 ribavirin 的 600-800 mg 为 24 wk 三次皮下地收到 interferon-alpha。结果:总的来说持续的 virological 反应(SVR ) ,在浆液的定义同样无法发现的 HCV RNA,在治疗的结束以后的 24 wk,在 84.4% 显著地高,(146/173 ) 由 intention-to-treat 分析。在 SVR 的有效差量有或没有 ribavirin (46.9% 对 92.9%) 的中止在病人之间被发现,但是没有差别有或没有 ribavirin 的剂量减小在那些之间被发现。在 SVR 的有效差量也与 16 或更与不到 16 wk 和病人在病人之间被发现 ribavirin 治疗(34.8% 对 92.0%) 的星期。结论:24-wk 干扰素和 ribavirin 治疗为有 HCV 遗传型 2 的日本病人是高度有效的。SVR 的重要预言者是 ribavirin 治疗的继续多达 16 个星期。 | Norihiro Furusyo Masaki Katoh Yuichi Tanabe Eiji Kajiwara Toshihiro Maruyama Junya Shimono Hironori Sakai Makoto Nakamuta Hideyuki Nomura Akihide Masumoto Shinji Shimoda Kazuhiro Takahashi Koichi Azuma Jun Hayashi Kyushu University Liver Disease Study Group | 2006 | World Journal of Gastroenterology2006，12，5： | 8 |
您所在的机构暂未开通此部分的功能，请联系管理员